A Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy in Local Advanced or Metastatic Non-small Cell Lung Cancer

• Status: Not yet recruiting
• Trial end date: 2027-10-31
• Target enrollment: 0
• Participant gender: All

Summary

This is a phase 3, open-label, randomized, multi-center study assessing the efficacy and safety of DZD9008 versus platinum-based doublet chemotherapy in participants with locally advanced or metastatic NSCLC with EGFR Exon20ins mutation, who are newly diagnosed or have not received prior systemic therapy in advanced stage.

Primary objective of this study is to assess the efficacy of DZD9008 versus platinum-based doublet chemotherapy using by BICR-assessed PFS per RECIST 1.1 as primary endpoint. Approximately 320 participants are estimated to be randomized into the study. Participants enrolled will be randomized to DZD9008 or platinum-based doublet chemotherapy in a 1:1 manner, stratified by baseline brain metastasis (with/without).

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Dizal Pharmaceuticals
• Treatments: Carboplatin; Pemetrexed

Criteria

Inclusion Criteria:

1. Aged at least 18 years old (or per local regulatory/IRB requirement).

2. Histologically or cytologically confirmed diagnosis of non-squamous NSCLC, locally advanced (Stage IIIB and IIIC according to the 8th edition of the AJCC TNM staging criteria) or metastatic (Stage IV), not suitable for curative therapy.

3. Adequate tumor tissue available, for central laboratory confirmation of EGFR exon 20 insertion mutation

4. At least 1 measurable lesion per RECIST Version 1.1

5. Life expectancy ≥ 12 weeks

6. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1

7. Adequate organ and hematologic function

Exclusion Criteria:

1. Prior treatment with any systemic anti-cancer therapy for locally advanced or metastatic NSCLC.

2. Spinal cord compression or leptomeningeal metastasis.

3. Concurrent EGFR mutations: exon 19 deletion, L858R, T790M, G719X, S768I, or L861Q.

4. History of stroke or intracranial hemorrhage within 6 months before randomization.

5. As judged by the investigator, any evidence of severe or uncontrolled systemic diseases, including uncontrolled hypertension and active bleeding diatheses (i.e., hemophilia and Von Willebrand disease).